Clinical trials: Bevacizumab
Colorectal Cancer, Pancreatic Cancer
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Trial name
- NCT04421820
- Testing
- BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 220 people
- Sponsor
- Bold Therapeutics, Inc.
Ovarian Cancer
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2…
- Trial name
- DO-01 (NCT06819007)
- Testing
- Trastuzumab Deruxtecan, Bevacizumab
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 582 people
- Sponsor
- Daiichi Sankyo
Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous…
- Trial name
- NCT07297212
- Testing
- Pumitamig, Bevacizumab, Temozolomide
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Colo-rectal Cancer
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
This is a non-registrational Phase 1/2, multicenter, open-label trial to evaluate the efficacy and safety of varsetatug masetecan combined with anti-cancer therapies in participants with unresectable metastatic colorectal cancer…
- Trial name
- NCT07900165
- Testing
- varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab
- Volunteers
- 368 people
- Sponsor
- CytomX Therapeutics
Metastatic Colorectal Cancer
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given…
- Trial name
- AndroMETa-CRC (NCT06820463)
- Testing
- Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin
- Where
- 82 sites in United States, Australia and 13 more
- Volunteers
- 390 people
- Sponsor
- AbbVie
Ras-mutated Metastatic Colorectal Cancer, mCRC
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs.
- Conditions
- Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
- Trial name
- NCT07446322
- Testing
- Bevacizumab, FOLFIRI, Pelareorep
- Where
- 19 sites in United States
- Volunteers
- 60 people
- Sponsor
- Oncolytics Biotech
Hepatocellular Carcinoma
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome…
- Trial name
- NCT04712643
- Testing
- Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE)
- Where
- 40 sites in China, Japan
- Volunteers
- 342 people
- Sponsor
- Hoffmann-La Roche
Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
- Trial name
- NCT07895355
- Testing
- RC148 plus Telisotuzumab adizutecan, Telisotuzumab adizutecan plus Bevacizumab
- Where
- China
- Volunteers
- 412 people
- Sponsor
- RemeGen Co., Ltd.
Non-squamous Non-small Cell Lung Cancer
SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined bevacizumab versus Sacituzumab Tirumotecan in the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer
- Trial name
- NCT07895992
- Testing
- SHR-A2009 + bevacizumab, Sacituzumab Tirumotecan
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Untreated, Unresectable, or Metastatic Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or…
- Trial name
- NCT07221357
- Testing
- Pumitamig, FOLFOX, FOLFIRI
- Where
- 286 sites in United States, Argentina and 23 more
- Volunteers
- 990 people
- Sponsor
- Bristol-Myers Squibb
Cancer
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during…
- Trial name
- IMbrella B (NCT03768063)
- Testing
- Atezolizumab, Bevacizumab, Alectinib
- Where
- 80 sites in United States, Australia and 22 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and…
- Trial name
- NCT05440708
- Testing
- TTI-101, Pembrolizumab, Atezolizumab
- Where
- 21 sites in United States
- Volunteers
- 193 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Colorectal Cancer
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as…
- Trial name
- NCT06547385
- Testing
- ONO-4578, ONO-4538, Capecitabine
- Where
- 9 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
- Trial name
- CANTOR (NCT06792695)
- Testing
- Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
- Where
- 56 sites in United States, Australia and 10 more
- Volunteers
- 82 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Ovarian Cancer Recurrent
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly.
- Trial name
- NCT06843447
- Testing
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel
- Where
- 39 sites in United States, Canada and 6 more
- Volunteers
- 605 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 7 sites in United States, Israel and 2 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Refractory Metastatic Colorectal Cancer
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and…
- Trial name
- DEL-LIVER (NCT06607458)
- Testing
- Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
- Where
- 20 sites in United States, Czechia and 7 more
- Volunteers
- 90 people
- Sponsor
- Delcath Systems Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Trial name
- NCT06890338
- Testing
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Where
- 73 sites in United States
- Volunteers
- 140 people
- Sponsor
- AbbVie
Advanced Microsatellite Stable Colorectal Cancer
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced…
- Trial name
- NCT07527858
- Testing
- Denikitug, Nivolumab, Bevacizumab
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Gilead Sciences